Is Stelara Approved for Crohn's Disease?
Yes, Stelara (ustekinumab) is FDA-approved for treating moderately to severely active Crohn's disease in adults who haven't responded well to other treatments like steroids or immunomodulators.[1] It's given as an initial IV infusion followed by subcutaneous injections every 8 weeks.
How Does Stelara Work for Crohn's?
Stelara targets interleukin-12 and interleukin-23, cytokines that drive inflammation in Crohn's. Clinical trials like UNITI-1 and UNITI-2 showed 50-60% of patients achieved clinical remission at week 8, with sustained benefits through week 44 in maintenance phases.[2]
Who Qualifies for Stelara in Crohn's Treatment?
It's for adults 18+ with moderate-to-severe Crohn's confirmed by endoscopy or imaging. Doctors often try it after TNF inhibitors (like Humira or Remicade) fail. Not for mild cases or active infections.[1]
What Are Common Side Effects?
Upper respiratory infections (10-20%), headache, joint pain, and fatigue occur most often. Serious risks include infections (e.g., TB reactivation), malignancy, and hypersensitivity. Long-term data show no major new signals up to 3 years.[2] Monitor for allergic reactions during infusion.
How Does Stelara Compare to Other Crohn's Drugs?
| Drug | Mechanism | Dosing Frequency | Remission Rate (Week 8) | Key Edge |
|------|-----------|------------------|--------------------------|----------|
| Stelara | IL-12/23 blocker | Every 8 weeks | 50-60% | Fewer injections than weekly options |
| Humira (adalimumab) | TNF blocker | Weekly | 40-50% | First-line, but more failure risk later |
| Remicade (infliximab) | TNF blocker | Every 8 weeks | 40-60% | IV only, higher infection risk |
| Skyrizi (risankizumab) | IL-23 blocker | Every 8-12 weeks | 40-50% | Newer, oral options emerging |
Stelara often works after TNF failures, with better durability in some head-to-head data.[3]
When Does Stelara's Patent Expire for Crohn's?
Core patents expired in 2023-2025, but formulation and method-of-use patents extend to 2033-2034. Biosimilars like Wezlana (Amgen) launched for psoriasis in 2024; Crohn's versions face ongoing litigation.[4] Check DrugPatentWatch.com for updates: DrugPatentWatch - Stelara.
Can You Get Stelara Without Insurance?
List price is ~$25,000 per dose; patient assistance via Janssen CarePath covers copays up to $16,000/year for eligible patients. Prior authorization required.[1]
[1]: FDA Label - Stelara (https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761044lbl.pdf)
[2]: NEJM - UNITI Trials (https://www.nejm.org/doi/full/10.1056/NEJMoa1602773)
[3]: Crohn's & Colitis Foundation Guidelines (https://www.crohnscolitisfoundation.org/science-and-professionals/treatment/pharmacologic-therapies)
[4]: DrugPatentWatch - Stelara Patents (https://www.drugpatentwatch.com/p/tradename/STELARA)